Dibromomannitol (NSC-94100): a clinical study of previously treated patients with refractory chronic myelocytic leukemia and blastic transformation.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D001966:Bromine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002066:Busulfan / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008353:Mannitol / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents; D008353:Mannitol; D002066:Busulfan; D001966:Bromine